Tourmaline Bio (TRML) Competitors $24.00 +0.50 (+2.13%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends TRML vs. LBPH, ARWR, PTGX, IDYA, KROS, CGON, WVE, AKRO, AMPH, and MIRMShould you be buying Tourmaline Bio stock or one of its competitors? The main competitors of Tourmaline Bio include Longboard Pharmaceuticals (LBPH), Arrowhead Pharmaceuticals (ARWR), Protagonist Therapeutics (PTGX), IDEAYA Biosciences (IDYA), Keros Therapeutics (KROS), CG Oncology (CGON), Wave Life Sciences (WVE), Akero Therapeutics (AKRO), Amphastar Pharmaceuticals (AMPH), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical products" industry. Tourmaline Bio vs. Longboard Pharmaceuticals Arrowhead Pharmaceuticals Protagonist Therapeutics IDEAYA Biosciences Keros Therapeutics CG Oncology Wave Life Sciences Akero Therapeutics Amphastar Pharmaceuticals Mirum Pharmaceuticals Tourmaline Bio (NASDAQ:TRML) and Longboard Pharmaceuticals (NASDAQ:LBPH) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, community ranking, analyst recommendations, risk and institutional ownership. Do insiders and institutionals have more ownership in TRML or LBPH? 91.9% of Tourmaline Bio shares are held by institutional investors. Comparatively, 63.3% of Longboard Pharmaceuticals shares are held by institutional investors. 11.0% of Tourmaline Bio shares are held by company insiders. Comparatively, 4.6% of Longboard Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is TRML or LBPH more profitable? Tourmaline Bio's return on equity of -20.97% beat Longboard Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Tourmaline BioN/A -20.97% -20.56% Longboard Pharmaceuticals N/A -33.03%-30.90% Does the media refer more to TRML or LBPH? In the previous week, Tourmaline Bio had 4 more articles in the media than Longboard Pharmaceuticals. MarketBeat recorded 5 mentions for Tourmaline Bio and 1 mentions for Longboard Pharmaceuticals. Longboard Pharmaceuticals' average media sentiment score of 0.52 beat Tourmaline Bio's score of 0.10 indicating that Longboard Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tourmaline Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Longboard Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation and earnings, TRML or LBPH? Longboard Pharmaceuticals is trading at a lower price-to-earnings ratio than Tourmaline Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTourmaline BioN/AN/A-$42.12M-$2.82-8.51Longboard PharmaceuticalsN/AN/A-$54.42M-$2.23-26.80 Does the MarketBeat Community believe in TRML or LBPH? Longboard Pharmaceuticals received 50 more outperform votes than Tourmaline Bio when rated by MarketBeat users. However, 100.00% of users gave Tourmaline Bio an outperform vote while only 75.00% of users gave Longboard Pharmaceuticals an outperform vote. CompanyUnderperformOutperformTourmaline BioOutperform Votes13100.00% Underperform VotesNo VotesLongboard PharmaceuticalsOutperform Votes6375.00% Underperform Votes2125.00% Do analysts recommend TRML or LBPH? Tourmaline Bio currently has a consensus target price of $65.00, indicating a potential upside of 170.83%. Longboard Pharmaceuticals has a consensus target price of $59.56, indicating a potential downside of 0.36%. Given Tourmaline Bio's stronger consensus rating and higher probable upside, equities research analysts clearly believe Tourmaline Bio is more favorable than Longboard Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tourmaline Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Longboard Pharmaceuticals 0 Sell rating(s) 5 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.44 Which has more risk & volatility, TRML or LBPH? Tourmaline Bio has a beta of 2.36, meaning that its share price is 136% more volatile than the S&P 500. Comparatively, Longboard Pharmaceuticals has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500. SummaryTourmaline Bio beats Longboard Pharmaceuticals on 12 of the 15 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide Get Tourmaline Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TRML and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRML vs. The Competition Export to ExcelMetricTourmaline BioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$602.61M$2.93B$5.04B$8.81BDividend YieldN/A1.89%5.16%4.07%P/E Ratio-8.5146.01130.5317.82Price / SalesN/A360.251,183.8674.55Price / CashN/A160.0933.6132.53Price / Book2.383.734.684.68Net Income-$42.12M-$41.63M$119.23M$226.08M7 Day Performance-10.71%-4.73%-1.83%-1.04%1 Month Performance-15.21%-6.53%-3.61%1.04%1 Year Performance36.44%25.63%31.74%26.28% Tourmaline Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRMLTourmaline Bio1.8572 of 5 stars$24.00+2.1%$65.00+170.8%+36.0%$602.60MN/A-8.5144LBPHLongboard Pharmaceuticals1.4763 of 5 stars$59.77-0.1%$59.56-0.4%+1,283.6%$2.33BN/A-26.8020ARWRArrowhead Pharmaceuticals3.574 of 5 stars$18.71+0.6%$45.33+142.3%-35.3%$2.31B$19.65M-4.01400Upcoming EarningsAnalyst ForecastPTGXProtagonist Therapeutics3.0192 of 5 stars$40.65+5.2%$53.57+31.8%+135.8%$2.30B$60M15.28125Analyst ForecastNews CoverageIDYAIDEAYA Biosciences4.1374 of 5 stars$25.54-1.2%$53.67+110.1%-17.1%$2.21B$23.39M-10.9680Analyst ForecastKROSKeros Therapeutics3.4923 of 5 stars$54.14+1.0%$88.89+64.2%+80.5%$2.19B$150,000.00-10.39100CGONCG Oncology3.1626 of 5 stars$32.24-1.7%$63.88+98.1%N/A$2.18B$684,000.000.0061Short Interest ↓Analyst RevisionWVEWave Life Sciences4.8489 of 5 stars$14.26+0.4%$21.89+53.5%+174.2%$2.17B$113.31M0.00240Analyst RevisionAKROAkero Therapeutics4.047 of 5 stars$30.64-1.3%$46.83+52.9%+83.8%$2.14BN/A-8.1730Analyst ForecastInsider TradeAMPHAmphastar Pharmaceuticals4.719 of 5 stars$44.09+1.1%$63.00+42.9%-22.1%$2.12B$644.40M14.701,761MIRMMirum Pharmaceuticals4.2959 of 5 stars$43.69+3.8%$57.73+32.1%+36.1%$2.10B$307.03M-21.63140Analyst Revision Related Companies and Tools Related Companies Longboard Pharmaceuticals Alternatives Arrowhead Pharmaceuticals Alternatives Protagonist Therapeutics Alternatives IDEAYA Biosciences Alternatives Keros Therapeutics Alternatives CG Oncology Alternatives Wave Life Sciences Alternatives Akero Therapeutics Alternatives Amphastar Pharmaceuticals Alternatives Mirum Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TRML) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tourmaline Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tourmaline Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
